Marked Truncal Acne Response to Sarecycline Monotherapy in Different Ethnicities

Angela Yen Moore1,2, Stephen Moore1,3, Luke Moore1, Ayman Grada4, Stephen K Tyring3

1Arlington Research Center, Arlington, TX, USA; 2Baylor University Medical Center, Dallas, TX, USA; 3Department of Dermatology, The University of Texas McGovern Medical School, Houston, TX, USA; 4Grada Dermatology Research LLC, Chesterbrook, PA, USA

INTRODUCTION

- 60-70% of patients present with acne on the trunk.1
- Since severity of truncal acne does not correlate with severity of facial acne, the psychosocial burden and physical pain and bleeding of truncal acne cannot be underestimated.2
- Oral antibiotics are the mainstream treatment for moderate-to-severe acne vulgaris.
- Sarecycline, a narrow-spectrum tetracycline-class drug, is FDA-approved for moderate-to-severe acne vulgaris in patients 9 years of age and older.
- Sarecycline exhibits potent anti-inflammatory activity and activity against C. acnes but reduced activity against Gram-negative bacteria commonly found in the gut; these characteristics may contribute to its low potential for antibiotic resistance and favorable safety and tolerability profile.3
- Significant improvement in truncal acne, using IGA assessments, was reported with sarecycline in Phase 3 clinical trials.4,5

METHODS

- We present 2 patients treated with sarecycline monotherapy for 3 months.
- At baseline, weeks 3, 6, 9 and 12, we assessed IGA scores and lesion counts change of the trunk.

RESULTS

**Inflammatory Lesion Count Reduction**

<table>
<thead>
<tr>
<th>Demographics</th>
<th>Baseline</th>
<th>3 Wks</th>
<th>6 Wks</th>
<th>9 Wks</th>
<th>12 Wks</th>
</tr>
</thead>
<tbody>
<tr>
<td>14 yo White male</td>
<td>47</td>
<td>22 (53%)</td>
<td>8 (83%)</td>
<td>1 (98%)</td>
<td>2 (96%)</td>
</tr>
<tr>
<td>13 yo Hispanic female</td>
<td>29</td>
<td>16 (45%)</td>
<td>4 (86%)</td>
<td>2 (93%)</td>
<td>3 (90%)</td>
</tr>
</tbody>
</table>

- No side effects of special interest for tetracycline-family antibiotics, including nausea, diarrhea, esophagitis, pseudotumor cerebri, blurry or double vision, dizziness, vertigo, or blue-gray pigmentation, were observed.

CONCLUSIONS

- This case series shows rapid improvement in IGA and reduction inflammatory lesion count with oral sarecycline, and confirms previously reported significant improvement of truncal acne in Phase 3 clinical trials.

CLINICAL IMPLICATIONS

- Sarecycline is an effective narrow-spectrum antibiotic alternative that can be utilized in treating truncal acne, especially when topical agents are challenging for the patients to apply due to surface area and location.

REFERENCES


**DISCLOSURES:** Research grant from Almirall, LLC.

**Baseline Data**

<table>
<thead>
<tr>
<th>Demographics</th>
<th>Skin Phototype</th>
<th>Truncal IGA</th>
<th>Truncal lesion count*</th>
<th>Facial lesion count*</th>
</tr>
</thead>
<tbody>
<tr>
<td>14 yo White male</td>
<td>2</td>
<td>4</td>
<td>47</td>
<td>8</td>
</tr>
<tr>
<td>13 yo Hispanic female</td>
<td>4</td>
<td>3</td>
<td>29</td>
<td>28</td>
</tr>
</tbody>
</table>

* Inflammatory lesions (papules and pustules)